News-Papers
Testimonial
Video Gallery
Melatonin and its contribution to tumor attenuation in systemic malignancies
Published on Thursday, 14 August 2014
Letter To The Editor
See also About Melatonin.
Search
Follow us...
Latest
- Serum 25-Hydroxyvitamin D Levels in Breast Cancer Patients: A Cross-Sectional Analysis by Molecular Tumor Subtypes
- The Role of Melatonin in Colorectal Cancer
- Assessment of the radioprotective effects of amifostine and melatonin on human lymphocytes irradiated with gamma-rays in vitro
- Effect of the preventive-therapeutic administration of melatonin on mammary tumour-bearing animals
- The role of melatonin in immuno-enhancement: potential application in cancer
- Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial
- Dose-Dependency of Antitumor Effects of the Pineal Hormone Melatonin in Untreatable Metastatic Solid Tumor Patients
- Beneficial properties of melatonin in an experimental model of pancreatic cancer
- Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling
- Understanding the role of melatonin in cancer metabolism
- Antiproliferative and Pro-Apoptotic Activity of Melatonin Analogues on Melanoma and Breast Cancer Cells
- Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer
- Prolactin inhibitors in oncology
- Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1
- A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin
- Adjuvant chemotherapy with melatonin for targeting human cancers: A review
- Does the use of melatonin overcome drug resistance in cancer chemotherapy?
- Melatonin as a Promising Agent to Treat Ovarian Cancer: Molecular Mechanisms
Most Read
- The Di Bella Method (DBM)
- About melatonin - 1996
- All-trans-retinoic acid and cancer
- Biography
- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
- Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
- Somatostatin in oncology, the overlooked evidences
- Bibliography
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
- How effective is chemo therapy?
- Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
- Complete objective response to biological therapy of plurifocal breast carcinoma
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
- Vademecum
- Frequently Asked Questions
- Declaration recommends eliminate the use of Impact factor for research evaluation
- Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
- Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer